Literature DB >> 27441096

Comparative Metabolism of Batracylin (NSC 320846) and N-acetylbatracylin (NSC 611001) Using Human, Dog, and Rat Preparations In Vitro.

Joseph M Covey1, Joel M Reid2, Sarah A Buhrow2, Mary Kuffel2, Chad Walden2, Holger Behrsing3, Matthew M Ames2.   

Abstract

BACKGROUND: Batracylin is a heterocyclic arylamine topoisomerase inhibitor with preclinical anticancer activity. Marked species differences in sensitivity to the toxicity of batracylin were observed and attributed to differential formation of N-acetylbatracylin by N-acetyltransferase. A Phase I trial of batracylin in cancer patients with slow acetylator genotypes identified a dose-limiting toxicity of hemorrhagic cystitis. To further explore the metabolism of batracylin and N-acetylbatracylin across species, detailed studies using human, rat, and dog liver microsomal and hepatocyte preparations were conducted.
METHODS: Batracylin or N-acetylbatracylin was incubated with microsomes and hepatocytes from human, rat, and dog liver and with CYP-expressing human and rat microsomes. Substrates and metabolites were analyzed by HPLC with diode array, fluorescence, radiochemical, or mass spectrometric detection. Covalent binding of radiolabeled batracylin and N-acetylbatracylin to protein and DNA was measured in 3-methylcholanthrene-induced rat, human, and dog liver microsomes, and with recombinant human cytochromes P450.
RESULTS: In microsomal preparations, loss of batracylin was accompanied by formation of one hydroxylated metabolite in human liver microsomes and five hydroxylated metabolites in rat liver microsomes. Six mono- or di-hydroxy-N-acetylbatracylin metabolites were found in incubations of this compound with 3MC rat liver microsomes. Hydroxylation sites were identified for some of the metabolites using deuterated substrates. Incubation with recombinant cytochromes P450 identified rCYP1A1, rCYP1A2, hCYP1A1 and hCYP1B1 as the major CYP isoforms that metabolize batracylin and N-acetylbatracylin. Glucuronide conjugates of batracylin were also identified in hepatocyte incubations. NADPH-dependent covalent binding to protein and DNA was detected in all batracylin and most N-acetylbatracylin preparations evaluated.
CONCLUSIONS: Microsomal metabolism of batracylin and N-acetylbatracylin results in multiple hydroxylated products (including possible hydroxylamines) and glutathione conjugates. Incubation of batracylin with hepatocytes resulted in production primarily of glucuronides and other conjugates. There was no clear distinction in the metabolism of batracylin and N-acetylbatracylin across species that would explain the differential toxicity.

Entities:  

Keywords:  Batracylin; Hepatocytes; Metabolism; Microsomes; N-Acetylbatracylin

Year:  2016        PMID: 27441096      PMCID: PMC4948755          DOI: 10.4172/2157-7609.1000203

Source DB:  PubMed          Journal:  J Drug Metab Toxicol


  16 in total

1.  Activity of batracylin (NSC-320846) against solid tumors of mice.

Authors:  P Mucci-LoRusso; L Polin; M C Bissery; F Valeriote; J Plowman; G D Luk; T H Corbett
Journal:  Invest New Drugs       Date:  1989-11       Impact factor: 3.850

2.  Preclinical antitumor activity of batracylin (NSC 320846).

Authors:  J Plowman; K D Paull; G Atassi; S D Harrison; D J Dykes; H J Kabbe; V L Narayanan; O C Yoder
Journal:  Invest New Drugs       Date:  1988-09       Impact factor: 3.850

3.  Toxicity of the heterocyclic amine batracylin: investigation of rodent N-acetyltransferase activity and potential contribution of cytochrome P450 3A.

Authors:  G J Stevens; J L Burkey; C A McQueen
Journal:  Cell Biol Toxicol       Date:  2000       Impact factor: 6.691

4.  Phase I clinical and pharmacological studies of 20-(S)-camptothecin and 20-(S)-9-nitrocamptothecin as anticancer agents.

Authors:  E A Natelson; B C Giovanella; C F Verschraegen; K M Fehir; P D De Ipolyi; N Harris; J S Stehlin
Journal:  Ann N Y Acad Sci       Date:  1996-12-13       Impact factor: 5.691

5.  Differences in N-acetylation of the experimental antitumor agent batracylin in the mouse and the rat.

Authors:  M M Ames; D A Mathiesen; J M Reid
Journal:  Invest New Drugs       Date:  1991-08       Impact factor: 3.850

Review 6.  Novel approaches in the synthesis of batracylin and its analogs: rebirth of an old player?

Authors:  K Dzierzbicka; W Januchta; A Skladanowski
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

7.  Pharmacogenetically driven patient selection for a first-in-human phase I trial of batracylin in patients with advanced solid tumors and lymphomas.

Authors:  Shivaani Kummar; Martin E Gutierrez; Lawrence W Anderson; Raymond W Klecker; Alice Chen; Anthony J Murgo; James H Doroshow; Jerry M Collins
Journal:  Cancer Chemother Pharmacol       Date:  2013-08-03       Impact factor: 3.333

8.  High-dose 7-hydromethotrexate: acute toxicity and lethality in a rat model.

Authors:  E Smeland; O M Fuskevåg; K Nymann; J S Svendesn; R Olsen; S Lindal; R M Bremnes; J Aarbakke
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

9.  A new antitumour agent, batracylin, selected by a preclinical solid tumour model.

Authors:  G Atassi; P Dumont; H J Kabbe; O Yoder
Journal:  Drugs Exp Clin Res       Date:  1988

10.  Activation of the antitumor agent aminoflavone (NSC 686288) is mediated by induction of tumor cell cytochrome P450 1A1/1A2.

Authors:  Mary J Kuffel; Jennifer C Schroeder; Lori J Pobst; Stephen Naylor; Joel M Reid; Scott H Kaufmann; Matthew M Ames
Journal:  Mol Pharmacol       Date:  2002-07       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.